Knight Therapeutics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Samira Sakhia
- Full Time Employees
- 830
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 100 Boul. Alexis-Nihon Montréal QC Canada H4M 2P2
- IPO Date
- Mar 3, 2014
- Website
- gud-knight.com
- Similar Companies
- Business
- Knight Therapeutics Inc. (TSX: GUD) is a pan-American (ex-U.S.) specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and commercializing innovative prescription pharmaceutical products in Canada and Latin America. Founded in 2013 and headquartered in Montreal, Quebec, the company operates through wholly-owned subsidiaries in Canada and 10 Latin American countries including Brazil, Mexico, Colombia, Argentina, Chile, Peru, Ecuador, Bolivia, Paraguay and Uruguay; it employs over 700 people globally and targets therapeutic areas such as oncology, hematology, infectious diseases and other specialties. Knight's core products include Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre (pemigatinib) for metastatic cholangiocarcinoma; Akynzeo and Aloxi for chemotherapy-induced nausea and vomiting prevention; Tavalisse (fostamatinib) for chronic immune thrombocytopenia; Karfib (carfilzomib) for multiple myeloma; Lenvima for thyroid cancer and hepatocellular carcinoma; Halaven for breast cancer; Palbocil/Bapocil (palbociclib) for breast cancer; Exelon and Impavido owned outright; as well as Qelbree (viloxazine), Imvexxy (estradiol vaginal inserts) and Bijuva (estradiol/progesterone) for ADHD and menopause symptoms; and pipeline assets such as Crexont (carbidopa/levodopa), Jornay PM (methylphenidate), Rembre (dasatinib) and Xetrane (pomalidomide). In recent developments, Knight closed a US$100 million secured revolving credit facility in October 2025 to support growth and acquisitions; entered a definitive asset purchase agreement in March 2025 with Endo Operations Limited and Paladin Pharma Inc. to acquire Paladin's international pharmaceuticals business for C$120 million upfront plus up to US$15 million in milestones, expected to close mid-2025 and adding over 50 products to its Canadian portfolio; launched Minjuvi in Brazil and Mexico approvals, Imvexxy/Bijuva in Canada, relaunched Akynzeo in multiple markets, obtained approvals for Pemazyre in Brazil/Argentina, Karfib in Colombia/Mexico, Tavalisse in Mexico and advanced pipeline submissions including Qelbree in Canada and oncology assets retifanlimab/axatilimab from Incyte; while completing a normal course issuer bid repurchasing 2 million shares and raising 2025 revenue guidance to $410-$420 million on record quarterly results.
Company News
Thérapeutique Knight inc. se hisse au 345e rang du huitième classement annuel du Globe and Mail des entreprises canadiennes à forte croissance
Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing Companies
Knight Therapeutics Q2 Earnings Call Highlights
Knight Therapeutics Announces Repayment of Revolving Credit Facility
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Brésil
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript
Knight Therapeutics Reports First Quarter 2026 Results
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call
Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
Thérapeutique Knight déclare ses résultats du quatrième trimestre et de la fin d’exercice de 2025
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
Avis de conférence téléphonique de Thérapeutique Knight sur ses résultats du quatrième trimestre et de fin d’année 2025
Knight Therapeutics (KHTRF) Expected to Announce Earnings on Thursday
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil